The prototype works.
The technology has been demonstrated.
The clinical need is clear.
The team is excited.
So why do so many promising MedTech innovations never become successful commercial products?
Because proving that something can work is very different from proving that it can be manufactured, regulated, adopted, supported and sold at scale.
Between those two points lies one of the most dangerous stages of MedTech development.
The valley of death.
And it is littered with good ideas.
The prototype can create a dangerous illusion
There is a moment in almost every innovation programme when the prototype starts working.
People can touch it. Investors can see it. Clinicians can try it. The technology suddenly feels real.
That creates momentum.
But it can also create false confidence.
A prototype usually answers one important question:
Can we make this work?
A commercial medical product has to answer many more.
Can we manufacture it consistently?
Can we manufacture it economically?
Can we verify and validate it?
Can we meet regulatory requirements?
Can real users operate it safely?
Can suppliers produce the components at the required quality and volume?
Can it survive transportation, storage and repeated use?
Can it be serviced?
Can healthcare systems integrate it?
Will somebody buy it?
And critically:
Can we still deliver the clinical and user benefit that made the original prototype exciting?
This is where innovation becomes product development.
Prototype success is not production readiness
Regulators understand this distinction very clearly.
FDA design control guidance specifically warns that successfully building and testing prototypes does not necessarily demonstrate that a device can be manufactured successfully at full scale. Equipment, tooling, personnel, procedures and manufacturing environments can all change when a product moves into routine production. (U.S. Food and Drug Administration)
That is why design transfer matters.
The FDA describes design transfer as the process of translating a device design into production specifications, and its quality framework requires manufacturers to consider verification, validation, risk, manufacturing and transfer into production. (U.S. Food and Drug Administration)
Yet development teams can underestimate just how significant that transition is.
Was your prototype designed to prove the concept, or designed to become the product?
They are not necessarily the same thing.
The expensive problems often arrive late
Imagine a connected diagnostic device.
The prototype performs beautifully.
Then industrialisation begins.
A critical component cannot be sourced reliably.
The enclosure is difficult to manufacture at the required tolerance.
Assembly takes too long.
A sensor behaves differently between batches.
The product fails an environmental test.
A design change affects usability.
Another change affects the regulatory documentation.
The manufacturing cost destroys the original business case.
None of these necessarily mean the original technology was bad.
The problem is that commercial realities arrived too late.
This is where apparently small development decisions can become expensive.
And it raises an uncomfortable question:
How many of the problems discovered during industrialisation could have been identified while the product was still cheap to change?
The valley isn’t just technical
This is where the phrase “valley of death” can be misleading.
It sounds like a funding problem.
Funding certainly matters. A 2026 UK Government review of technology commercialisation identified limited funding and internal capacity amongst the most commonly cited barriers, with organisations themselves referring to the funding “valley of death”. (GOV.UK)
But money alone doesn’t turn prototypes into products.
The real challenge is convergence.
Clinical need has to converge with engineering.
Engineering with manufacturing.
Manufacturing with economics.
Design with human factors.
Human factors with regulation.
Regulation with evidence.
Evidence with reimbursement and procurement.
And all of them with a commercial proposition somebody actually wants.
If those conversations happen sequentially, problems accumulate.
If they happen together, risks can be exposed much earlier.
Design for manufacture, but also design for business
Design for manufacture is well understood.
But perhaps MedTech companies need to think more broadly about design for commercialisation.
Consider a relatively simple question:
What does this product need to cost?
Not what does the prototype cost today.
What does the finished product need to cost for the business model to work?
That answer affects materials, components, manufacturing processes, assembly, packaging, servicing, logistics and supply chain.
Now ask another:
Who makes the purchasing decision?
The answer might influence the evidence you generate, the claims you pursue and even the functionality you prioritise.
And another:
What has to happen inside the healthcare system for somebody to actually use it?
That could fundamentally change the workflow, interface, connectivity or training requirements.
This is why commercialisation cannot simply be handed to a commercial team once development is finished.
The commercial product has to be designed from the beginning.
More process isn’t necessarily the answer
Large MedTech organisations have rigorous development processes for good reason.
Medical devices need control, documentation and evidence.
But at the earliest stages of innovation, excessive structure can also make experimentation slow and expensive.
There is another approach.
Put a small multidisciplinary team around the problem.
Designers.
Engineers.
Human factors specialists.
Digital specialists.
Manufacturing expertise.
Regulatory understanding.
Commercial thinking.
Give them permission to challenge the proposition rather than simply execute the brief.
Build quickly.
Test quickly.
Break things while they are still inexpensive to fix.
Ask difficult questions before the organisation becomes emotionally and financially committed to the answer.
What would make this product fail?
What assumptions haven’t we tested?
What happens when we manufacture 10,000 rather than ten?
What will the regulator challenge?
What will frustrate the clinician?
What will stop procurement?
Where does the business case break?
Finding reasons why an idea might fail isn’t pessimism.
It is how you increase its chances of succeeding.
Prototype less. Learn more.
This may sound counterintuitive for a product development consultancy.
But sometimes the objective shouldn’t be to make the prototype more polished.
It should be to make it more informative.
A crude prototype that exposes a fundamental usability problem can be more valuable than a beautiful demonstrator.
An early manufacturing exercise that identifies a cost problem can save months of development.
A conversation with procurement can invalidate a commercial assumption before an expensive clinical programme begins.
A human factors study can reveal that a clever feature actually creates risk.
The question shouldn’t be:
“How quickly can we get to the next prototype?”
It should be:
“What do we need to learn next?”
Build the commercial product backwards
At Maddison, we believe the best way to cross the valley of death is to start thinking about the destination much earlier.
What does commercial success look like?
What does the user need?
What does the healthcare system need?
What will regulation require?
What must manufacturing deliver?
What does the business model tolerate?
Then work backwards.
That is why our approach brings product design, engineering, human factors, UX, manufacturing and commercial thinking together around the same problem.
For larger MedTech organisations, an experienced external team can also create space to explore opportunities rapidly outside the constraints and competing priorities of the core development organisation.
Not every idea should survive.
The objective is to identify the ones that should, then give them the engineering, design and commercial foundations needed to scale.
Because the graveyard of MedTech innovation isn’t filled only with bad ideas.
It is filled with promising prototypes that were never successfully turned into products.
So where is your next innovation heading, towards another prototype, or towards a commercial product?
References
- US Food and Drug Administration, Design Control Guidance for Medical Device Manufacturers, including guidance on design transfer and production feasibility.
- US Food and Drug Administration, PMA Quality System, design controls, verification, validation and transfer to production.
- Medical Device Single Audit Program, MDSAP Audit Approach, design transfer and production requirements.
- UK Government, Government Office for Technology Transfer: Theory of Change Review, 2026, barriers to technology commercialisation.
- Department of Health and Social Care, Medical Technology Innovation Classification Framework, 2024, challenges surrounding assessment, funding, procurement and adoption of MedTech innovation.